Literature DB >> 22349638

Reactive oxygen species and aldehyde dehydrogenase activity in Hodgkin lymphoma cells.

Jun-ichiro Ikeda1, Suhana Mamat, Tian Tian, Yi Wang, Wenjuan Luo, Nur Rahadiani, Katsuyuki Aozasa, Eiichi Morii.   

Abstract

Tumor cells with tumorigenic potential might be limited to a small population of cells, called cancer-initiating cells (CICs). CICs efficiently form colonies in vitro, yield both CIC and non-CIC populations, maintain reactive oxygen species (ROS) at low levels, show high aldehyde dehydrogenase (ALDH) activity, and are mostly in a quiescent state of the cell cycle. CICs of Hodgkin lymphoma (HL) are small in size, with low levels of ROS. The relationship between ROS level and ALDH activity in CICs was examined in HL cell lines. ROS-low and ALDH-high populations formed colonies in semi-solid cultures more efficiently than ROS-high and ALDH-low populations. ALDH-high populations yielded both ALDH-low and -high populations, whereas ALDH-low populations rarely yielded an ALDH-high population. The number of cells in a quiescent state was significantly greater in ROS-low than in ROS-high cells, whereas that of ALDH-high and ALDH-low cells was comparable to each other. These findings show that ALDH-high and ROS-low cells share CIC-like potential, but they differ in their cell cycle status, suggesting that CICs are comprised of cells with heterogeneous characteristics.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22349638     DOI: 10.1038/labinvest.2012.4

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  15 in total

Review 1.  Reactive oxygen species in eradicating acute myeloid leukemic stem cells.

Authors:  Hui Zhang; Hai Fang; Kankan Wang
Journal:  Stem Cell Investig       Date:  2014-06-07

2.  Requirement of CXCL12-CXCR7 signaling for CD20(-) CD138(-) double-negative population in lymphoplasmacytic lymphoma.

Authors:  Naoki Wada; Jun-Ichiro Ikeda; Satoshi Nojima; Shin-Ichiro Tahara; Kenji Ohshima; Daisuke Okuzaki; Eiichi Morii
Journal:  Lab Invest       Date:  2016-02-15       Impact factor: 5.662

3.  ID1 upregulation and FoxO3a downregulation by Epstein-Barr virus-encoded LMP1 in Hodgkin's lymphoma.

Authors:  Jun-Ichiro Ikeda; Naoki Wada; Satoshi Nojima; Shinichiro Tahara; Yoko Tsuruta; Kaori Oya; Eiichi Morii
Journal:  Mol Clin Oncol       Date:  2016-09-08

4.  Characterization of subpopulation lacking both B-cell and plasma cell markers in Waldenstrom macroglobulinemia cell line.

Authors:  Naoki Wada; Maosheng Zhan; Yumiko Hori; Keiichiro Honma; Jun-ichiro Ikeda; Eiichi Morii
Journal:  Lab Invest       Date:  2013-11-04       Impact factor: 5.662

5.  ALDH1A1 mediates resistance of diffuse large B cell lymphoma to the CHOP regimen.

Authors:  Ying-Hui Song; Mei-Zuo Zhong; Ping-Ping Gan; Ping-Yong Yi; You-Hong Tang; Yi-Ping Liu; Jin-Qiong Jiang; Li Li
Journal:  Tumour Biol       Date:  2014-10-25

6.  Sca-1+ cells from fetal heart with high aldehyde dehydrogenase activity exhibit enhanced gene expression for self-renewal, proliferation, and survival.

Authors:  Devaveena Dey; Guodong Pan; Nadimpalli Ravi S Varma; Suresh Selvaraj Palaniyandi
Journal:  Oxid Med Cell Longev       Date:  2015-03-10       Impact factor: 6.543

Review 7.  Aldehyde dehydrogenase 1A1 in stem cells and cancer.

Authors:  Hiroyuki Tomita; Kaori Tanaka; Takuji Tanaka; Akira Hara
Journal:  Oncotarget       Date:  2016-03-08

Review 8.  Heterogeneity of tumor cells in terms of cancer-initiating cells.

Authors:  Eiichi Morii
Journal:  J Toxicol Pathol       Date:  2016-09-25       Impact factor: 1.628

Review 9.  Aldehyde Dehydrogenases: Not Just Markers, but Functional Regulators of Stem Cells.

Authors:  Giuseppe Vassalli
Journal:  Stem Cells Int       Date:  2019-01-13       Impact factor: 5.443

Review 10.  Drug Resistance Driven by Cancer Stem Cells and Their Niche.

Authors:  Marta Prieto-Vila; Ryou-U Takahashi; Wataru Usuba; Isaku Kohama; Takahiro Ochiya
Journal:  Int J Mol Sci       Date:  2017-12-01       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.